Literature DB >> 26586194

Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication.

Se-Jun Park1, Chong-Suh Lee2, Sung-Soo Chung1.   

Abstract

BACKGROUND CONTEXT: A number of studies have reported favorable surgical results for metastatic spinal tumors from various solid tumors. However, there are few data available on metastatic spinal cord compression (MSCC) from lung cancer despite its considerable frequency.
PURPOSE: The study aims to present the functional outcomes, survival time, and complications after surgical treatment for MSCC from non-small cell lung cancer (NSCLC). STUDY DESIGN/
SETTING: This is a longitudinal observational study. PATIENT SAMPLE: The study includes 50 patients who had neurologic deficit and underwent surgical treatment for MSCC from NSCLC. OUTCOME MEASURES: The Eastern Cooperative Oncology Group performance status (ECOG-PS), ambulatory status, overall survival, factors associated with survival time, and perioperative complications were analyzed.
METHODS: The postoperative changes of ECOG-PS and ambulatory status were assessed. The factors affecting postoperative ambulatory status were evaluated using logistic regression analysis. Survival time was calculated using the Kaplan-Meier method. To identify the prognostic factors, log-rank test and Cox hazards regression model were used for univariate and multivariate analyses, respectively. Major complications within postoperative 30 days and mortality rate were recorded.
RESULTS: The study cohort consisted of 27 males and 23 females with a mean age of 58.0±11.3 years at the time of surgery. An ECOG-PS improvement by at least one grade was observed in 33 of 50 cases (66.0%). Among 39 patients who were not ambulatory before surgery, 23 patients (59.0%) regained ambulatory ability after surgery. Patients who were preoperatively ambulant and those who underwent surgery within 72 hours from neurologic deficit had an increased chance of postoperative ambulation. The median for overall survival after surgery was 5.2 months. Five prognostic factors were identified on univariate analysis: time from neurologic deficit, responsiveness to preoperative chemotherapy, postoperative chemotherapy, postoperative ECOG-PS, and postoperative ambulatory status. Multivariate analysis revealed that time to neurologic deficit (risk ratio [RR]: 2.28, p=.023), postoperative chemotherapy (RR: 6.58, p<.001), and postoperative ECOG-PS (RR: 2.73, p=.040) were independent prognostic factors of survival time. Major complications developed in 34.0% of patients (17 of 50), and the 30-day mortality rate was 10.0% (5 of 50).
CONCLUSIONS: Functional improvements were observed through surgical treatment even with relatively high complication rates for MSCC from NSCLC. Earlier surgical treatment could act as an adjuvant therapy for prolonging survival by improving functional status.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Chemotherapy; Decompression surgery; Metastatic spinal cord compression; Non–small cell lung cancer; Spinal metastases; Surgical treatment

Mesh:

Year:  2015        PMID: 26586194     DOI: 10.1016/j.spinee.2015.11.005

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  19 in total

1.  The next generation in surgical research for patients with spinal metastases.

Authors:  Andrew J Schoenfeld; Marco L Ferrone
Journal:  Spine J       Date:  2018-07-26       Impact factor: 4.166

2.  Ambulatory status after surgical and nonsurgical treatment for spinal metastasis.

Authors:  Andrew J Schoenfeld; Elena Losina; Marco L Ferrone; Joseph H Schwab; John H Chi; Justin A Blucher; Genevieve S Silva; Angela T Chen; Mitchel B Harris; James D Kang; Jeffrey N Katz
Journal:  Cancer       Date:  2019-04-15       Impact factor: 6.860

3.  Maverick total disc arthroplasty performs well at 10 years follow-up: a prospective study with HRQL and balance analysis.

Authors:  N Plais; X Thevenot; A Cogniet; J Rigal; J C Le Huec
Journal:  Eur Spine J       Date:  2017-04-05       Impact factor: 3.134

4.  Minimal Access Surgery for Spinal Metastases: Prospective Evaluation of a Treatment Algorithm Using Patient-Reported Outcomes.

Authors:  Ori Barzilai; Lily McLaughlin; Mary-Kate Amato; Anne S Reiner; Shahiba Q Ogilvie; Eric Lis; Yoshiya Yamada; Mark H Bilsky; Ilya Laufer
Journal:  World Neurosurg       Date:  2018-09-04       Impact factor: 2.104

Review 5.  Evaluating ambulatory function as an outcome following treatment for spinal metastases: a systematic review.

Authors:  Lananh Nguyen; Nicole Agaronnik; Marco L Ferrone; Jeffrey N Katz; Andrew J Schoenfeld
Journal:  Spine J       Date:  2021-05-13       Impact factor: 4.297

6.  Metastatic spinal cord compression (MSCC) treated with palliative decompression: Surgical timing and survival rate.

Authors:  Wan-Yu Lo; Shu-Hua Yang
Journal:  PLoS One       Date:  2017-12-29       Impact factor: 3.240

7.  Comparison of percutaneous vertebroplasty with and without interventional tumor removal for spinal metastatic tumor without epidural involvement.

Authors:  Yan Su; Zhong-Zhen Sun; Long-Xiang Shen; Jian Ding; Zheng-Yu Xu; Yi-Min Chai; Wen-Qi Song; Dong Chen; Chun-Gen Wu
Journal:  J Bone Oncol       Date:  2016-12-23       Impact factor: 4.072

8.  Prognostic factors in patients with metastatic spine tumors derived from lung cancer-a novel scoring system for predicting life expectancy.

Authors:  Hiroshi Uei; Yasuaki Tokuhashi
Journal:  World J Surg Oncol       Date:  2018-07-05       Impact factor: 2.754

9.  Prognostic factors and its predictive value in patients with metastatic spinal cancer.

Authors:  Qing-Peng Gao; Da-Zhi Yang; Zheng-Bin Yuan; Yu-Xia Guo
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

10.  Treatment Outcome of Metastatic Spine Tumor in Lung Cancer Patients: Did the Treatments Improve Their Outcomes?

Authors:  Hiroshi Uei; Yasuaki Tokuhashi; Masafumi Maseda
Journal:  Spine (Phila Pa 1976)       Date:  2017-12-15       Impact factor: 3.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.